𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pharmacokinetics and protein binding of methocarbamol in renal insufficiency and normals

✍ Scribed by D. A. Sica; T. J. Comstock; J. Davis; L. Manning; R. Powell; A. Melikian; G. Wright

Publisher
Springer
Year
1990
Tongue
English
Weight
216 KB
Volume
39
Category
Article
ISSN
0031-6970

No coin nor oath required. For personal study only.

✦ Synopsis

We determined plasma methocarbamol concentrations over 24 h following a 1.5 g methocarbamol dose (off-dialysis day) to 8 chronic haemodialysis patients and compared these results to those from 17 healthy male volunteers. The harmonic mean elimination half-life was similar between the two groups, 1.24 and 1.14 h, respectively. tmax and the weight-adjusted Cmax were 1.1 h and 27.0 mg.m-1 for haemodialysis patients and 1.1 and 23.1 mg.l-1 for normals. Relative systemic availability was assessed by comparing weight-normalized AUC x k10 products. These results indicate no significant differences with respect to methocarbamol absorption, with the relative systemic availability in patients being 113%. These data suggest that absorption and elimination of methocarbamol is similar between normal subjects and patients undergoing maintenance haemodialysis.

πŸ“œ SIMILAR VOLUMES

Pharmacokinetics and bioavailability of
Pharmacokinetics and bioavailability of methocarbamol in rats
✍ R. Obach; J. PruΓ±onosa; A. Menargues; M. Nomen; J. VallΓ¨s πŸ“‚ Article πŸ“… 1988 πŸ› John Wiley and Sons 🌐 English βš– 467 KB πŸ‘ 1 views

In a pharmacokinetic study, 15, 30, 60, and 150 mg kg-' intravenous and oral doses of methocarbamol were administered to rats. Differences observed in plasma clearance values, i.e. 0~0203,0~0156,0~0123, and 0-0085 1 kg-' min-' for 15,30,60, and 150 mg kg-', respectively, suggested a dosedependent ph

Cyclophosphamide pharmacokinetics and do
Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency
✍ Haubitz, Marion; Bohnenstengel, Frank; Brunkhorst, Reinhard; Schwab, Matthias; H πŸ“‚ Article πŸ“… 2002 πŸ› Nature Publishing Group 🌐 English βš– 219 KB

## Background: Intravenous pulse administration of cyclophosphamide (cyc) has been successfully used for the treatment of various autoimmune diseases. these patients often present with impaired renal function or even end-stage renal failure. nevertheless, data concerning pharmacokinetics of cyc in